Carl Zeiss agrees collaboration with Oraya

Oraya therapy for wet macular degeneration

https://www.reuters.com/article/crl-zeis-meditec-oraya/carl-zeiss-agrees-collaboration-with-oraya-idUSL6N0U63HG20141222

FRANKFURT, Dec 22 (Reuters) - Germany’s Carl Zeiss Meditec said late on Monday it had signed a deal with Oraya Therapeutics under which it will provide funding to the U.S.-based firm for its growth strategy for up to two years.

In return, Carl Zeiss Meditec will receive rights to a stake in Oraya, reaching up to a majority, after two years, the company said, without saying how much funding it would provide to the U.S.-based firm.

Oraya has over the past few years developed a low energy radiation therapy called “Oraya Therapy” for the eye disease wet age-related macular degeneration (wet AMD) and introduced it to the market, according to Carl Zeiss Meditec.

Wet AMD is a leading cause of blindness among the elderly. (Reporting by Maria Sheahan; editing by Andrew Hay)

The Oraya therapy is offered, among others, by the University Eye Clinic Lübeck

Overview Oraya Therapy for wet macular degeneration